Mogroside aerosol and preparation method thereof

A mogroside and inhalation powder spray technology, applied in the field of medicine, can solve the problems of unsatisfactory treatment effect and the like, and achieve the effects of low clinical use price, rapid absorption and low preparation cost

Active Publication Date: 2019-10-08
GUILIN EIGHT PLUS ONE PHARMA CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, the treatment ef

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mogroside aerosol and preparation method thereof
  • Mogroside aerosol and preparation method thereof
  • Mogroside aerosol and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1 Investigation on the preparation process of mogroside superfine powder

[0039]In order to better deposit the drug in the lungs, the drug particles in the inhaled powder should be mainly distributed in the range of 1 μm to 5 μm. The fourth part of the "2015 Chinese Pharmacopoeia" stipulates that the particle size of raw materials in inhalation preparations should be controlled below 10 μm, and most of them should be below 5 μm. After inhalation, particles with too small particle size diffuse in the form of Brownian motion in bronchioles and alveoli and other parts with slow airflow, making it difficult to settle, and are easy to be exhaled with the expiratory airflow.

[0040] In this experiment, the superfine powder of mogroside was prepared by wet ball milling, and the preparation process of mixed drug powder was optimized by star-point design-response surface method. E40) 8g, placed in a 100ml stainless steel ball mill jar, the grinding medium is stainless...

Embodiment 2

[0043] Example 2 Selection of Lactose in the Preparation Technology of Mogroside Inhalation Powder

[0044] Mogroside MFC-E40 (Gifuss (China) Luo Han Guo Co., Ltd.), lactose for inhalation 120 (Germany MEGLE Group), 230 (Megel Group, Germany), 400 (German MEGLE Group), 3 # Hypromellose Empty Capsules (Suzhou Capsule Co., Ltd.)

[0045] The particle size distribution and fluidity of lactose for inhalation used in this research are shown in the table below, 120、 The particle size distribution range of 230 is larger than 400, the content of fine powder with a particle size of less than 15 μm is also less, so the fluidity is better, and it has a stronger effect on improving the fluidity of mogroside inhalation powder. 120、 230.

[0046] Table 1 Particle size distribution and fluidity of lactose for inhalation

[0047]

Embodiment 3

[0048] Example 3 Fluidity Evaluation in the Preparation Process of Mogroside Inhalation Powder

[0049] Mogroside superfine powder and carrier lactose 120、 230 were mixed according to 1:2, 1:4, 1:6 respectively, passed through 80-mesh sieve 10 times, and mixed well to obtain. A total of 6 different prescriptions of mogroside inhalation powder and aerosol pharmaceutical powder were prepared, and the fluidity measurement results of each prescription are shown in Table 2.

[0050] Table 2 Different prescription fluidity measurement results (n=3)

[0051]

[0052] It can be seen from Table 2 that adding lactose can significantly improve the fluidity of mogroside superfine powder. Mogroside superfine powder is very easy to aggregate and agglomerate, and has a high angle of repose (70.28 degrees), and its fluidity is expressed by the degree of compression, which can reach 50.28%, indicating that the fluidity is extremely poor. joining In the prescription of 120, as the pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
Maximum particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to the technical field of medicine, in particular to a mogroside aerosol and a preparation method thereof. The mogroside aerosol is prepared by mixing ultrafine powder of mogroside and fine powder of lactose, wherein the mass ratio of the ultrafine powder of mogroside to the fine powder of lactose is 1 to (2 to 6). The mogroside aerosol has the beneficial effects that the mogroside inhalation powder aerosol can be autonomously and actively inhaled by patients through an inhalation device, the medicine is transported to the lungs to take effect, and the systemic toxic andside effects of the medicine are reduced; inhalation can be autonomously performed without the help of medical staff, and the mogroside aerosol is convenient to use; and the preparation cost is low, and the clinical use price is relatively low.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a mogroside aerosol and a preparation method thereof. Background technique [0002] Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease (ILD), in which the interstitium, alveolar epithelial cells, and surrounding connective tissue are inflamed to varying degrees, resulting in inflammatory damage and Pulmonary interstitial fibrosis appeared during the repair process, and the clinical manifestations were mostly progressive dyspnea and cough. The affected lung function is mainly manifested as restrictive ventilatory dysfunction and decreased diffusing capacity. At present, the research on the pathogenesis of IPF continues to deepen, and most scholars believe that environmental factors (inhalation of smog, dust, metal powder, wood chips, etc.) and smoking are the main potential pathogenic factors. [0003] The pathogenesis of pulmonary interstitial fibrosis ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/72A61K9/12A61K47/26A61K31/704A61P11/00
CPCA61K9/0073A61K31/704A61K47/26A61P11/00
Inventor 邓鹏陈珊韦飞雪唐春王宝艺文艺邹豪
Owner GUILIN EIGHT PLUS ONE PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap